Issues that may influence selection of a factor concentrate for treatment of patients with hemophilia B, including whether the product is derived from plasma or is of recombinant origin, costs, pharmacokinetic issues, and safety considerations, are discussed in this paper. Data in the published literature, advice from the medical team, and patient and family preferences, will also impact product choice. Plasma-derived and recombinant products have similar efficacy; however, recombinant concentrates are more expensive and have demonstrated lower post-infusion recovery, and plasma-derived concentrates may be perceived as less safe. Improvements in donor selection and testing, viral inactivation, and product purification have greatly reduced potential risks of plasma-derived products. It is expected that both recombinant and plasma-derived products will continue to be used worldwide in the treatment of hemophilia B.
[1]
P. Mannucci.
Hemophilia: treatment options in the twenty‐first century
,
2003,
Journal of thrombosis and haemostasis : JTH.
[2]
M. Haase.
Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates.
,
2002,
Blood.
[3]
D. Lillicrap,et al.
Recombinant Factor IX Recovery and Inhibitor Safety: A Canadian Post-licensure Surveillance Study
,
2002,
Thrombosis and Haemostasis.
[4]
K. Zakrzewska,et al.
TT virus contaminates first-generation recombinant factor VIII concentrates.
,
2001,
Blood.
[5]
M. Hannan,et al.
Safety and efficacy of monoclonal antibody purified factor IX concentrate in previously untreated patients with hemophilia B.
,
1996,
Thrombosis and Haemostasis.